|  Help  |  About  |  Contact Us

Publication : Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia.

First Author  Tomic J Year  2011
Journal  Blood Volume  117
Issue  9 Pages  2668-80
PubMed ID  21205928 Mgi Jnum  J:170359
Mgi Id  MGI:4946358 Doi  10.1182/blood-2010-05-285999
Citation  Tomic J, et al. (2011) Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia. Blood 117(9):2668-80
abstractText  The type I interferons (IFNs) normally suppress tumor growth by phosphorylating and activating the signal transducer and activator of transcription 1 (STAT1), but also briefly activate STAT3, which promotes cell growth. In chronic lymphocytic leukemia (CLL) cells, the duration of IFN-mediated STAT3 phosphorylation was found to exhibit significant interpatient variability and was prolonged in cells with high risk features, such as 11q- and 17p- deletions involving ataxia telangiectasia mutated (ATM) and p53. This aberrant signaling pattern was associated with a paradoxical increase in cell size and number in response to IFN and similar alterations in IFN-signaling and responses were seen in cell lines that developed in the absence of p53 or ATM. However, direct inhibition of p53 or ATM failed to cause these changes, and CLL cells with aggressive clinical features were found to also express high levels of reactive oxygen species (ROS), which decrease tyrosine phosphatase activity. Prolonged IFN-mediated STAT3 phosphorylation and lowered phosphatase activity could be reversed by antioxidants. These findings suggest that increased ROS levels may corrupt IFN-signaling processes in aggressive CLL cells, causing IFN to be used as a growth factor rather than a tumor suppressor. Antioxidants or STAT3 kinase inhibitors might improve the outcome of IFN therapy in CLL by restoring normal signaling.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

3 Authors

6 Bio Entities

0 Expression